Physician profile
Christopher A Johns
NPI 1144675992
$3,284.97
in general payments reported to CMS, 2019-2025
25 companies · $371 in 2025
The $371 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $282 · 2021: $377 · 2022: $1,439 · 2023: $412 · 2024: $405 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,187.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,772.98 | 2022-2025 | Intellis Adaptivestim, Inceptiv |
| Amgen INC. | $267.59 | 2020-2025 | Evenity, Prolia |
| Collegium Pharmaceutical, INC. | $191.63 | 2022-2025 | Belbuca, Xtampza |
| Abbott Laboratories | $162.31 | 2020-2024 | Proclaim |
| Boston Scientific Corporation | $137.92 | 2025 | Wavewriter Alpha Prime 16 |
| Vertex Pharmaceuticals Incorporated | $103.26 | 2024-2025 | |
| Allergan, INC. | $91.12 | 2020-2021 | |
| Pfizer INC. | $82.58 | 2020-2021 | |
| Ferring Pharmaceuticals INC. | $70.49 | 2020-2021 | |
| Biodelivery Sciences International, INC. | $56.19 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $39.65 | 2021 | |
| Ibsa Pharma INC. | $37.02 | 2021 | |
| Bioventus LLC | $36.28 | 2021-2024 | Durolane |
| Abbvie INC. | $34.98 | 2021 | |
| Scilex Pharmaceuticals INC. | $34.04 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanos Medical | $25.10 | 2025 | Generator |
| Fidia Pharma USA INC. | $24.96 | 2024 | Hymovis |
| Nevro Corp. | $17.41 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.55 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $15.40 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.17 | 2022 | |
| International Rehabilitative Sciences, INC | $14.93 | 2024 | Rs 4i Plus Sequential Stimulator |
| Merz North America, INC. | $13.48 | 2020 | |
| Medtronic USA, INC. | $12.60 | 2020 | |
| Redhill Biopharma INC. | $12.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Johns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.